Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Table 4. Univariate analyses of patients with or without 30% pain relief by mirogabalin

Variables	< 30% pain relief (n= 50)	≥ 30% pain relief (n= 113)	pvalue
Age (years)	72.9 ± 11.9 (45–88)	71.3 ± 13.0 (30–94)	0.46^a
Sex, female/male	30/20	82/31	0.11^b
Diagnosis			0.75^b
LCS	35	83
CSM	11	17
LDH	2	7
CTS	2	6
Others	0	1
BMI (kg/m²)	22.7 ± 4.2 (18–33)	23.0 ± 3.8 (19–31)	0.79^a
DM	4	11	0.72^b
NeP score (points)	7.4 ± 2.1 (6–12)	6.6 ± 1.4 (6–12)	0.0047^a
Primary doze (mg)	3.1 ± 1.5 (5–10)	3.1 ± 1.1 (5–10)	0.97^a
Max dose (mg)	6.6 ± 3.8 (5–30)	6.4 ± 3.8 (5–30)	0.76^a
Adverse events	24 (48%)	42 (37.2%)	0.13^b
Somnolence	17 (34%)	27 (23.9%)
Dizziness	6 (12%)	10 (8.8%)
Edema	2 (4%)	5 (4.4%)
Weight gain	1 (2%)	0 (0%)

Data are expressed as the mean ± standard deviation (range) or n (%).
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes mellitus, NeP neuropathic pain
^a Student’s t-test
^b Chi-squared test

ISSN: 1749-799X